2.595
前日終値:
$2.61
開ける:
$2.65
24時間の取引高:
91,117
Relative Volume:
0.13
時価総額:
$167.81M
収益:
-
当期純損益:
$-36.95M
株価収益率:
-3.0893
EPS:
-0.84
ネットキャッシュフロー:
$-33.46M
1週間 パフォーマンス:
-14.19%
1か月 パフォーマンス:
-22.16%
6か月 パフォーマンス:
-63.89%
1年 パフォーマンス:
-70.10%
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
LRMR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
LRMR
Larimar Therapeutics Inc
|
2.595 | 167.81M | 0 | -36.95M | -33.46M | -0.84 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
510.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
671.38 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
259.84 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-29 | 開始されました | Truist | Buy |
2024-10-16 | 開始されました | Oppenheimer | Outperform |
2024-10-03 | 開始されました | Wedbush | Outperform |
2024-10-02 | 開始されました | H.C. Wainwright | Buy |
2024-09-04 | 開始されました | Robert W. Baird | Outperform |
2024-04-03 | 開始されました | Leerink Partners | Outperform |
2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
2022-10-19 | 開始されました | Guggenheim | Buy |
2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World
Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St
BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com
Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex
Larimar Therapeutics Inc (LRMR)’s stock chart: A technical perspective - US Post News
Analysts Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.13 - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Truist Financial - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by JPMorgan Chase & Co. - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Buy” from Analysts - Defense World
Truist Financial Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar started at buy by Truist on Friedreich's ataxia drug - MSN
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com
This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Larimar Therapeutics awards key executives performance-based stock By Investing.com - Investing.com Australia
Larimar Therapeutics Aligns Executive Incentives with Milestones - MSN
Larimar Therapeutics awards key executives performance-based stock - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment - MSN
JMP Securities maintains $21 target on Larimar Therapeutics stock - MSN
Larimar Therapeutics (NASDAQ:LRMR) Earns “Buy” Rating from HC Wainwright - Defense World
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Sells 6,488 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics’ SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Nigeria
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics, Inc. Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Marketscreener.com
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Business Upturn
Larimar Therapeutics Announces Dosing of Adolescents in - GlobeNewswire
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN
Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43 - MarketBeat
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock - Yahoo Finance
Geode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):